GV

GV Management Company, LLC, established in 2009 as the venture capital arm of Alphabet Inc., specializes in investments across various stages, including seed, early, and late-stage funding. Based in Mountain View, California, with additional offices in Boston, New York, Seattle, Cambridge, and London, GV focuses on sectors such as life sciences, healthcare, artificial intelligence, robotics, transportation, cybersecurity, and agriculture. The firm has invested in over 300 companies, aiming to drive innovation and improve lives. GV seeks to make investments of up to $50 million, while offering early-stage startups funding of up to $250,000, typically taking minority stakes in these companies. Through its extensive network, GV provides startups with unique access to technology and talent, enhancing their potential for success.

Karim Faris

General Partner

Crystal Huang

Partner

Rick Klau

Partner

David Krane

Managing Partner

Daniel Lynch

Executive Venture Partner

David P. Schenkein

General Partner

KJ Sidberry

Principal

Krishna Yeshwant

General Partner

Sangeen Zeb

General Partner

Past deals in Early Venture Stage

Comanche Biopharma

Venture Round in 2023
Comanche Biopharma is a biopharmaceutical company that develops siRNA therapy for the treatment of preeclampsia.

Pretzel Therapeutics

Series A in 2022
Pretzel was founded by some of the world’s foremost academics in mitochondrial biology, and we benefit from the leadership of accomplished experts in drug discovery, drug development, and company formation. Our name is inspired by the focal point of our science, the mitochondrion, whose highly folded inner membrane is one of many fascinating features that make it unlike any other organelle in the body.

Omni

Series A in 2022
Omni is the only BI platform that combines the consistency of a shared data model with the freedom of SQL. Omni was founded in 2022 and was headquartered in California, United States.

Vicinitas Therapeutics

Series A in 2022
Vicinitas Therapeutics is a biotech startup that specializes in developing medicines that impact patient lives. Its vision is to use its proprietary Deubiquitinase Targeting Chimera (DUBTAC) platform to restore the levels of aberrantly degraded proteins that cause disease to confer therapeutic benefit.

Xilis

Series A in 2022
Xilis, Inc. develops next generation organoid technologies to guide precision therapy for cancer patients and improve drug discovery. It offers The XilisµO, a platform that enables rapid diagnostics, personalized drug screening, and scalable patient-derived models for high-throughput drug discovery. Xilis, Inc. was founded in 2019 and is based in Chapel Hill, North Carolina.

Areteia Therapeutics

Series A in 2022
Areteia Therapeutics is a biotechnology company committed to putting asthma patients in better control of their disease. The company was spun out of Pennsylvania-based Knopp, which published results from its phase 2 clinical trial last year that showed its oral drug candidate could reduce the count of blood eosinophil, which is an indication of improving lung function and is found in several asthma-related treatments.

FYTO

Series A in 2022
FYTO provides innovative solutions which improve the economic and environmental sustainability of agriculture for farmers around the world. FYTO is developing: NOVEL NUTRIENT-DENSE CROPS that have ultra-high yields and ultra-low resource requirements, STATE-OF-THE ART CULTIVATION AND HARVESTING SYSTEMS for exceptional quality and consistency, CLIMATE-FRIENDLY METHODOLOGIES for resiliency and long-term sustainability, and a range of GROUNDBREAKING AGRICULTURAL PRODUCTS such as animal feed and biofertilizer.

Sanas

Series A in 2022
Sanas is a technology company that specializes in real-time accent translation services, aimed at reducing language barriers and facilitating clearer communication. Its innovative software allows users to speak in various accents without any noticeable lag, enabling better understanding among speakers. The solution is designed to be user-friendly, operating locally on devices, which gives individuals complete control over their accent-matching preferences. By providing the option to adjust accents during conversations, Sanas enhances communication experiences and promotes inclusivity in interactions.

Ahana

Series A in 2022
Ahana was founded as the first company focused on bringing PrestoDB-based ad hoc analytics offerings to market and working to foster growth and evangelize the Presto community. While Presto is in large-scale production deployment at large internet companies like Facebook, Uber, and Twitter, Ahana’s mission is to simplify ad hoc analytics for organizations of all shapes and sizes. We are an “All Remote” company, from the start.

Strella Biotechnology

Series A in 2022
Strella Biotechnology, Inc. designs and manufactures sensors based device that maximizes the freshness of fresh produce throughout the supply chain. The company provides an ethylene-detection device that determines ripeness by calculating the ethylene gas produced by fruit and maximizes freshness and reduces spoilage of fruit. Strella Biotechnology, Inc. was founded in 2018 and is based in Philadelphia, Pennsylvania.

deepset

Series A in 2022
We are building the next enterprise search engine fueled by NLP and open-source. Building on top of latest NLP research we leverage question answering & transfer learning to provide granular, semantic search results tailored to different domains.

Veza

Venture Round in 2022
Cookie.AI is a stealth-mode startup based in the Silicon Valley / Bay Area. We are building SaaS based security products in a dynamic and fast moving world of cybersecurity with ideas rooted in the era of privacy for the cloud. We are well-funded and backed by top-tier VCs and CEOs as angel investors. The founders are serial entrepreneurs who have experience in the full 0-to-1 journey with a successful exit with an acquisition. We are looking for founding engineers (summer interns also welcome!) with strong interests in security / cloud-native systems / identity / SaaS.

Waltz Health

Series A in 2022
Waltz Health operates in the pharmaceutical supply chain, focusing on creating innovative, technology-driven solutions for pricing, distribution, and prescription of medications. The company develops consumer tools aimed at guiding decisions related to prescription care, with a particular emphasis on the needs of both payers and consumers. By utilizing AI-driven marketplaces, Waltz Health seeks to reduce costs and enhance the decision-making process for users. Their offerings provide better pricing information and resources that empower consumers while assisting payers in managing their pharmacy benefits more effectively.

Rooser

Series A in 2022
Rooser connects seafood buyers and suppliers across Europe, providing them with the tools they need to trade efficiently, negotiate prices, and process deliveries. Rooser is located in Edinburgh, Scotland.

Gravity Sketch

Series A in 2022
Gravity Sketch is powering enterprise teams that need to think, collaborate, and create in three dimensions. They build intuitive multi-platform tools to radically improve the efficacy and efficiency of developing 3D products. Their energy is focussed entirely on their customers - removing friction from their archaic workflows, helping enhance and expedite their creative intent, and ultimately, making collaboration in cross-functional teams faster and more cost-effective. It was founded in 2014 and is headquartered in London, England.

Rattle

Series A in 2022
Rattle is a technology company that offers a Salesforce integration solution aimed at enhancing the efficiency of sales and customer experience teams. By allowing users to access and manage Salesforce directly through Slack, Rattle addresses common challenges related to Salesforce adoption. This integration enables sales representatives to log calls, track essential metrics, and update opportunities seamlessly, facilitating real-time visibility into customer relationship management. The platform has proven effective for industry leaders, saving sales representatives an average of 30 minutes per day in pipeline management and reducing data hygiene issues by up to 50%. Rattle's solution ultimately allows marketing professionals to focus more on customer engagement rather than internal processes.

Agolo

Series A in 2022
Agolo summarizes information faster and with broader coverage than any human. It also uses artificial intelligence to create summaries from your information in real-time. The company helps analysts act strategically instead of processing information. Agolo’s technology replicates the ingenuity of the human mind by analyzing content through the identification of various subjects and drawing connections between them. The company’s AI platform can analyze thousands of documents and produce a summary of the five key points, specific to the reader’s interests, in real-time. Agolo was founded in 2012 and is headquartered in New York, NY, USA.

Bonnet

Venture Round in 2022
Bonnet Ltd., founded in 2019 and based in London, develops a charging-as-a-service platform that simplifies access to public electric vehicle chargers. The company aims to alleviate the inconvenience faced by drivers who must register for multiple charging networks. Bonnet offers a subscription service that enables users, both individuals and businesses, to utilize any public charger through a single account. The platform not only provides access to a comprehensive network of charging points across Europe but also features real-time charger availability information and contactless payment options. This approach enhances the user experience while promoting a more visible and accessible charging infrastructure for businesses.

Overview

Series A in 2022
Overview.ai provides real time fault detection that uses cameras and AI to monitor manufacturing robots, shutting them down if something goes wrong. Its smart camera automatically learns normal machine routines to detect any deviations, crashes or anomalies. Its system catches misalignments, breakage, and out-of-sequence behavior before significant damage occurs to product or machine.

Neo.tax

Series A in 2022
Neo.tax is a tax preparation and filing service based in Mountain View, California, that specializes in assisting early-stage startups. The company offers a tax automation platform that employs machine learning algorithms to streamline the collection and organization of data from various sources, including emails, documents, project management tools, and financial systems. This technology generates comprehensive reports that detail all activities, expenses, and methodologies used to claim tax credits. By enhancing accuracy and simplifying the review process, Neo.tax aims to ensure that businesses are audit-ready, thereby facilitating a more efficient and reliable tax filing experience.

Seismic Therapeutic

Series A in 2022
Seismic Therapeutic is a biotechnology company focused on accelerating immunology drug development through the integration of machine learning in the biologics discovery process. Utilizing its IMPACT™ platform, Seismic Therapeutic aims to tackle key challenges in biologics discovery by combining structural biology, protein engineering, and translational immunology. This comprehensive approach facilitates the creation of optimized therapies that can reach patients more quickly. The company is developing a pipeline of innovative biologics targeting adaptive immune system dysregulation, with the goal of treating autoimmune diseases.

TenSixteen Bio

Series A in 2022
TenSixteen Bio is a biotechnology company focused on developing novel therapeutics for a variety of diseases. The company uses somatic mosaicism and clonal hematopoiesis (CHIP) to find and develop new treatments for age-related disorders. Foresite Labs co-founded TenSixteen Bio, which is based in San Francisco.

Wonder

Series A in 2021
Wonder is a gaming company focused on developing an all-in-one gaming platform specifically for Android mobile devices. The platform enables users to play, stream, and share games seamlessly across different devices, thereby enhancing the overall gaming experience. Additionally, Wonder is exploring VR-ready gaming hardware to further enrich its offerings. Currently, the company operates in stealth mode, indicating that it is in the early stages of development and not yet publicly available.

Patina

Series A in 2021
We believe everyone should have the opportunity to live their best lives and age with dignity. That’s why we’re reinventing primary care with an approach designed to profoundly improve the healthcare and aging experience for older adults and their loved ones.

Modern Age

Series A in 2021
Modern Age is a health and wellness platform focused on improving the aging process for individuals. It offers health monitoring software that employs computer vision and machine learning to assess skin, hair, and bone health. The platform also integrates data collected from smart bands to create a comprehensive digital record of an individual's well-being. By analyzing this information, Modern Age provides personalized insights and treatment recommendations, empowering users to manage their health more effectively and lead healthier lives as they age.

Resistant AI

Series A in 2021
Resistant AI protects the machine learning system from adversarial manipulation and advanced fraud. We believe that responsible and systematic adoption of machine learning techniques can profoundly improve our lives. Our mission is to accompany our customers on this way and to ensure that the risks related to machine learning and AI adoption are responsibly detected, managed and resolved.

Sprinter Health

Series A in 2021
Sprinter Health is an on-demand mobile health company that sends full-time nurses and phlebotomists (“Sprinters”) into the home.

Matter

Series A in 2021
Matter operates as a social reading app for articles, blogs, and newsletters. The company is based in the United States.

Altana AI

Series A in 2021
Altana AI specializes in developing artificial intelligence software solutions focused on enhancing global trade. Founded in 2018 and based in New York, the company leverages comprehensive global economic data to provide visibility across borders and improve risk management for governments, enterprises, and financial institutions. Altana's offerings include AI-based data fusion and decision support tools, centered around the Altana Trade Knowledge Graph. This innovative platform delivers a real-time overview of transactions, ownership, movements, cyber activity, and associated risks within the global trade network. By facilitating better data-driven insights, Altana aims to make trade safer, more efficient, and more profitable for its clients, including regulators, businesses, financial service providers, and logistics companies.

Ahana

Series A in 2021
Ahana was founded as the first company focused on bringing PrestoDB-based ad hoc analytics offerings to market and working to foster growth and evangelize the Presto community. While Presto is in large-scale production deployment at large internet companies like Facebook, Uber, and Twitter, Ahana’s mission is to simplify ad hoc analytics for organizations of all shapes and sizes. We are an “All Remote” company, from the start.

Nym

Venture Round in 2021
Nym Health Inc. specializes in developing advanced medical coding technology aimed at enhancing revenue cycle processes within healthcare facilities. Its flagship product, Nym, offers a direct-to-billing autonomous coding solution that significantly reduces claims denials and operational costs while accelerating payment cycles and ensuring audit-readiness. The platform automatically identifies and captures relevant clinical information from patient charts, assigning codes only to fully understood cases; unhandled charts are sent back for human coding. Additionally, Nym provides a detailed audit-trail view that explains the rationale behind each coding decision, facilitating quick comprehension for validation, compliance, and appeals purposes. Founded in 2017 and headquartered in Boston, Massachusetts, the company also maintains a research and development center in Tel Aviv-Yafo, Israel.

Xilis

Series A in 2021
Xilis, Inc. develops next generation organoid technologies to guide precision therapy for cancer patients and improve drug discovery. It offers The XilisµO, a platform that enables rapid diagnostics, personalized drug screening, and scalable patient-derived models for high-throughput drug discovery. Xilis, Inc. was founded in 2019 and is based in Chapel Hill, North Carolina.

Dyno Therapeutics

Series A in 2021
Dyno Therapeutics Inc. specializes in the development of adeno-associated virus (AAV) vectors for in vivo delivery of gene therapies. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes an artificial intelligence-driven approach that integrates DNA synthesis, sequencing, and machine learning. This innovative methodology enables the design of novel gene vectors with an emphasis on cell-targeting capsid proteins derived from AAV, which is recognized as the most commonly used vector in gene therapy applications. By leveraging quantitative high-throughput in vivo experimentation, Dyno Therapeutics aims to enhance the effectiveness and precision of gene therapy solutions.

Nearby

Series A in 2021
Nearby is a computer software company that helps businesses and companies to connect with nearby customers. The company helps businesses put their inventory online, and adds their store to the marketplace for their town.

Treeline Biosciences

Series A in 2021
Treeline Biosciences is a biotech company building transformative precision medicines for patients with cancer and other serious conditions. The company was founded in 2021 and is headquartered in Stamford, CT.

Leyden Labs

Series A in 2021
Leyden Labs aims to help people live their lives to the fullest. Its platform targets commonalities of viral families to protect humanity from known and future viruses. Its portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The Company’s energetic team of world-renown biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses.

nPlan

Series A in 2021
nPlan limited designs and develops artificial intelligence (AI) based construction project management software. The company's solution uses machine learning technology to provide schedule certainty for projects, highlights risks by detecting gaps in the task performance pattern, and suggests execution paths. The software also makes recommendations to address residual issues and provides statistical risk attribution for each individual activity. The company was incorporated in 2017 and is based in London, United Kingdom.

Blockchain

Venture Round in 2021
Blockchain.com operates a comprehensive platform that enables users to buy, hold, and utilize cryptocurrencies, aiming to create an accessible financial system for the internet. With over 50 million users, it offers a straightforward method for engaging with digital currencies, including features for trading, sending, receiving, securing, and borrowing them. The platform also includes a widely used explorer for tracking crypto market activities and an exchange that facilitates fast trading experiences. Additionally, Blockchain Ventures, supported by Blockchain.com, invests in distributed ledger technology (DLT) projects that foster societal benefits and advance the industry, promoting innovative applications of DLT beyond financial services. Overall, Blockchain.com seeks to revolutionize the financial landscape by enabling quick transactions without intermediaries and providing essential tools for real-time market insights.

SpyBiotech

Series A in 2021
SpyBiotech Limited, founded in 2017 and based in Oxford, United Kingdom, specializes in the development of innovative vaccines through its proprietary biotechnology platform. The company utilizes a unique molecular superglue to bond antigens to viruses and other particles, facilitating the rapid creation of vaccines aimed at a variety of diseases. This advanced technology enables medical institutions and research centers to produce next-generation vaccines that demonstrate improved efficacy and reduced development time, thereby enhancing the overall vaccine development process.

Nothing

Series A in 2021
Nothing is removing the barriers between people and technology to create a seamless digital future.

Redpanda Data

Series A in 2021
Redpanda is a queue for people who deal with massive data streams.

Redpanda

Series A in 2021
Social Media Marketing Platform.

Air Protein

Series A in 2021
Air Protein, based in Berkeley, California, is a startup focused on creating sustainable protein from carbon dioxide using a proprietary probiotic process. This innovative technology allows the company to develop protein-enriched food products, such as meat-free burgers, pasta, cereals, and beverages, without the use of hormones, pesticides, or herbicides. By utilizing elements from the air, Air Protein's method significantly reduces the land and water required compared to traditional meat production, providing a sustainable alternative for consumers who seek to enjoy protein-rich foods while minimizing environmental impact. The company is a venture of Kiverdi, a biotechnology firm dedicated to advancing food sustainability.

IconOVir Bio

Series A in 2021
IconOVir Bio is a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer.

Found

Series A in 2021
Found is dedicated to improving people’s overall wellbeing by making evidence based weight loss accessible & affordable for all.

PostHog

Series A in 2020
PostHog is increasing the number of successful products in the world. We do that by providing a platform for open-source product analytics. This helps software teams understand user behaviour. We took part in Y Combinator’s W20 cohort, and had the most successful B2B software launch on HackerNews since 2012, with a product that was just 4 weeks old. Our team is a combination of former CTOs and YC founders all turned developers, alongside some of the best developers from the world's largest tech companies who have the experience to help us handle scalability. We're all remote, and we've raised enough to pay top of market. We are proudly backed by some of the best VCs and Investors in the world, such as Y Combinator. We believe in product-led growth, while we build something awesome and let our product bring the users, rather than an outbound sales team and regular cold calls. Check out posthog.com/careers if you want to be part of this journey.

Olive

Venture Round in 2020
Olive AI, Inc. specializes in artificial intelligence and robotic process automation solutions tailored for healthcare organizations. The company provides an AI-as-a-Service platform designed to streamline various workflows, including claim status checks, account updates, and prior authorizations. Founded in 2012 and headquartered in Columbus, Ohio, Olive aims to alleviate the burden of repetitive, high-volume tasks through automation, allowing healthcare professionals to focus on more complex responsibilities that require human creativity and empathy. Originally established as CrossChx, Inc., the company rebranded to Olive AI, Inc. in July 2018, reflecting its commitment to enhancing operational efficiency in the healthcare sector.

Spotlight Therapeutics

Series A in 2020
Spotlight Therapeutics is a developer of gene editing therapeutics intended to edit specific cell populations directly in the body. The company's therapeutics are used to create next-generation programmable nucleases that can selectively target and edit cells, enabling physicians to treat their patient in an enhanced way.

Spotlight Therapeutics

Series A in 2020
Spotlight Therapeutics is a developer of gene editing therapeutics intended to edit specific cell populations directly in the body. The company's therapeutics are used to create next-generation programmable nucleases that can selectively target and edit cells, enabling physicians to treat their patient in an enhanced way.

Headway

Series A in 2020
Headway is a mental healthcare system provider based in New York, established in 2019 by founders Andrew Adams, Jake Sussman, Dan Ross, and Kevin Chan. The company focuses on improving access to mental health services by developing a health insurance advisory platform that connects patients with therapists who traditionally do not accept insurance. In addition to facilitating these connections, Headway offers administrative support to therapists, enhancing their ability to provide care while navigating the complexities of insurance processes. Through this approach, Headway aims to make mental healthcare more accessible and efficient for both patients and providers.

Nym

Series A in 2020
Nym Health Inc. specializes in developing advanced medical coding technology aimed at enhancing revenue cycle processes within healthcare facilities. Its flagship product, Nym, offers a direct-to-billing autonomous coding solution that significantly reduces claims denials and operational costs while accelerating payment cycles and ensuring audit-readiness. The platform automatically identifies and captures relevant clinical information from patient charts, assigning codes only to fully understood cases; unhandled charts are sent back for human coding. Additionally, Nym provides a detailed audit-trail view that explains the rationale behind each coding decision, facilitating quick comprehension for validation, compliance, and appeals purposes. Founded in 2017 and headquartered in Boston, Massachusetts, the company also maintains a research and development center in Tel Aviv-Yafo, Israel.

Pixie

Series A in 2020
Pixie Labs Inc. specializes in developing tools that enhance application management within Kubernetes environments. Founded in 2018 and based in San Francisco, the company offers a zero-touch, unsampled edge monitoring system that enables developers to instantly debug applications without altering code or manually configuring dashboards. Its platform seamlessly integrates with any Kubernetes environment through a single command, automatically collecting baseline performance data and presenting it in pre-configured live views. This functionality allows developers to efficiently explore, monitor, secure, and manage their applications, providing essential insights into production environments.

Censys

Series A in 2020
Censys, Inc. is a cybersecurity company specializing in internet scanning and asset identification solutions. Founded in 2017 and based in Ann Arbor, Michigan, Censys provides an internet device search engine that allows users to discover and analyze devices connected to the Internet, including computers, servers, and smart devices. The platform is utilized for various applications such as attack surface management, monitoring remote workforces, and identifying potential threats. Censys is recognized for delivering real-time visibility and risk assessments, making it a valuable resource for researchers, corporations, and government entities. The company's data-driven security solutions are employed by notable organizations, including FireEye, Google, NATO, and the U.S. Department of Homeland Security, to enhance their cybersecurity measures and proactively address threats.

Invivyd

Series A in 2020
Invivyd is a biotechnology company focused on developing advanced antibodies to neutralize SARS-CoV-2, SARS-CoV-1, and other potentially emerging coronaviruses. Founded in 2020 and headquartered in Waltham, Massachusetts, the company aims to create best-in-class therapeutic and prophylactic treatments that surpass the efficacy of existing antibody programs. Its innovative portfolio features multiple non-competing antibodies, each targeting distinct viral epitopes, which is designed to minimize the risk of viral escape. By leveraging cutting-edge antibody discovery technologies, Invivyd seeks to enhance the potency and durability of its antibody candidates, addressing a critical need in the ongoing fight against coronaviruses.

Snorkel AI

Series A in 2020
Snorkel AI, Inc. is a technology company that specializes in developing an end-to-end machine-learning platform designed for building, managing, and monitoring AI applications. Central to its offerings is Snorkel Flow, a data-first platform that enables users to programmatically label and augment training data, manage and integrate data for AI purposes, and train and deploy various models. The platform also facilitates the extraction of entities and relationships from complex documents and ranks content based on relevance. This technology is beneficial across multiple sectors, including finance, government, telecommunications, insurance, healthcare, and e-commerce. Founded in 2016 and based in Palo Alto, California, Snorkel AI is committed to making AI practical through its innovative tools and solutions.

Fauna

Series A in 2020
Fauna, Inc. offers a cloud-based data application programming interface (API) designed for serverless applications, primarily through its product, FaunaDB. This NoSQL database combines a distributed transactional query engine with robust scalability and policy-based security features. FaunaDB provides a web-native GraphQL API that can be accessed from browsers, mobile clients, or serverless functions, while its serverless query language (FQL) enhances development by allowing complex queries that integrate various data types. The platform supports a wide array of programming languages and frameworks, including JavaScript, Python, and Ruby, facilitating seamless connections for developers. Fauna's database solutions emphasize unified capabilities across relational, temporal, and graph data, ensuring consistent performance and strong security measures. Founded in 2011 and headquartered in San Francisco, Fauna has garnered trust from notable clients like Nextdoor and NVIDIA and is supported by prominent venture capital investors.

Sana Biotechnology

Series A in 2020
Sana Biotechnology focuses on creating and delivering engineered cells as medicine for patients. Recent scientific advances make it possible to reprogram cells in the body or replace damaged cells and tissues, creating a new class of medicines to treat a broad array of diseases. The company is a team of scientists, clinicians and biotechnology veterans focused on creating an enduring company that makes meaningful medicines and will change the approach in treating diseases.

Verve Therapeutics

Series A in 2020
Verve Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies aimed at editing the adult human genome to reduce the risk of coronary artery disease, a leading cause of death globally. Founded in 2018 and headquartered in Cambridge, Massachusetts, with a research facility in Philadelphia, the company leverages human genetic analysis and gene-editing technologies to create treatments that offer lifelong protection from this condition. Verve has established strategic alliances, including collaborations with Beam Therapeutics to advance delivery technologies targeting cardiovascular issues and with Verily for developing gene editing delivery vehicles. Formerly known as Endcadia, Verve Therapeutics rebranded in September 2019 to reflect its commitment to addressing heart disease through advanced genetic solutions.

Owkin

Series A in 2020
Owkin is an artificial intelligence company founded in 2016, with headquarters in New York and an additional office in Paris. The company focuses on developing machine learning software for medical research, enabling researchers to test AI models on distributed data. Owkin's offerings include Owkin Lab, which facilitates data connectivity by therapeutic area; Owkin Loop, which provides validated and packaged models; and a comprehensive software stack for full-stack services. The company currently has 30 live models and an additional 40 in development. Owkin aims to empower medical researchers in hospitals, universities, and pharmaceutical companies to better understand variations in drug efficacy among patients, enhance the drug development process, and identify optimal treatments for individual patients, ultimately improving treatment outcomes. The company is supported by various investors and has a scientific board to guide its research initiatives.

Ventus Therapeutics

Series A in 2020
Ventus Therapeutics U.S., Inc. is a biopharmaceutical company based in Natick, Massachusetts, with an additional location in Montreal, Canada. Founded in 2019, it focuses on discovering and developing novel small-molecule medicines that target the innate immune system to address autoimmune diseases, inflammatory diseases, and cancer. The company employs a structural immunology platform that integrates protein engineering to elucidate molecular structures and mechanisms of action. This platform facilitates the development of precise binding and functional screening assays, as well as structure-based modeling. Ventus Therapeutics is advancing an emerging pipeline of drug programs aimed at key targets within the innate immune system, leveraging its proprietary capabilities in rational and structure-based drug design.

ROME Therapeutics

Series A in 2020
ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Established in 2019, ROME Therapeutics is pioneering the exploration of the repeatome, which consists of extensive regions of genetic material previously considered "junk DNA." The company has identified several drug targets and is actively advancing multiple discovery programs. To facilitate its research, ROME has assembled a team of experts across various disciplines, including oncology, immunology, virology, and machine learning, to harness this uncharted area of biology for therapeutic advancements.

Alkira

Series A in 2020
Alkira, Inc. is a provider of a network cloud platform that enables businesses to establish multi-cloud network connectivity quickly and efficiently. Founded in 2018 and headquartered in San Jose, California, Alkira offers a pay-as-you-go service that allows customers to connect their local systems and cloud workloads to its Cloud Exchange Points (CXP). The platform supports on-demand activation of security and other services, which can automatically scale based on usage. Alkira's Network Cloud integrates network and security services, provides comprehensive operational visibility, and features advanced controls for governance. Users can easily design their network across various users, sites, and clouds using an intuitive digital canvas, enabling rapid provisioning and deployment. Alkira's solutions are utilized by Fortune 100 companies, prominent system integrators, and managed service providers, marking its significant presence in the network-as-a-service sector.

Universe

Series A in 2020
Universe is a mobile-based website builder established in 2014 and headquartered in Brooklyn, New York. The platform aims to empower users to create customized websites quickly and easily, catering to the needs of small business owners and individuals who prefer mobile solutions. By offering a unique approach that eliminates complicated templates, Universe utilizes customizable website filters that allow users to arrange photos, videos, and icons on a grid pattern through a simple drag-and-drop interface. This enables users to build mobile-optimized websites in just minutes using the company's iOS app, providing them with full control over their online presence.

Dandelion Energy

Series A in 2020
Dandelion Energy offers affordable geothermal heating and cooling installations. Dandelion Energy's home geothermal system replaces your home’s existing air conditioning and heating equipment with a powerful heat pump and safe, underground pipes that move heat between the earth and home. Kathleen Hannun and Rajeez Quazi founded it in 2017, with its headquarters in Palo Alto in California.

EQRx

Series A in 2020
EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before. The company was founded in 2019 and is based in Cambridge, Massachusetts, United States.

Merlin Labs

Series A in 2020
Merlin Labs is building an autonomous infrastructure for the sky above us, enabling goods, and eventually people, to fly without pilots.

Kindbody

Series A in 2019
Kindbody operates a health and tech company intended to offer fertility services and treatments for the modern woman. It offers a full range of services including intrauterine insemination, in-vitro fertilization, donor support, egg freezing, and embryo freezing, enabling women to improve their overall health and wellbeing.

Kindbody

Series A in 2019
Kindbody operates a health and tech company intended to offer fertility services and treatments for the modern woman. It offers a full range of services including intrauterine insemination, in-vitro fertilization, donor support, egg freezing, and embryo freezing, enabling women to improve their overall health and wellbeing.

Kronos Bio

Series A in 2019
Kronos Bio focuses on the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. It develops therapies that modulate historically undruggable targets. The company leverages deep capabilities in high-throughput small-molecule microarrays (SMM), targeted protein degradation, and cancer biology in order to identify potent and selective compounds against transcription factors and other central drivers of oncogenic signaling.

Firefly

Series A in 2019
Firefly Systems Inc., founded in 2017 and based in San Francisco, California, specializes in street-level digital media through its innovative advertising platform. The company installs digital displays on rideshare vehicles and taxis, creating a unique out-of-home advertising network that leverages location-based technology and first-party data for precise audience targeting. Firefly's system enables the delivery of engaging, full-screen advertisements that are responsive to the surrounding environment, allowing brands to amplify their marketing efforts in real-time. By utilizing 4G and LTE cellular transmission, Firefly connects clients with flexible advertising solutions while providing measurable insights on campaign effectiveness and audience engagement.

Locanabio

Series A in 2019
Locanabio, Inc., is an RNA-targeting gene therapy company focused on developing therapies for patients with severe neurodegenerative, neuromuscular, and retinal diseases.

Verve Therapeutics

Series A in 2019
Verve Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies aimed at editing the adult human genome to reduce the risk of coronary artery disease, a leading cause of death globally. Founded in 2018 and headquartered in Cambridge, Massachusetts, with a research facility in Philadelphia, the company leverages human genetic analysis and gene-editing technologies to create treatments that offer lifelong protection from this condition. Verve has established strategic alliances, including collaborations with Beam Therapeutics to advance delivery technologies targeting cardiovascular issues and with Verily for developing gene editing delivery vehicles. Formerly known as Endcadia, Verve Therapeutics rebranded in September 2019 to reflect its commitment to addressing heart disease through advanced genetic solutions.

Insitro

Series A in 2019
Insitro is a operator of a data-driven drug discovery and development company that uses machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients. The company uses state-of-the-art technologies from Bioengineering enabling it to generate high-throughput, functional genomic data sets and aligning them with patient data via a novel machine learning methods, thereby building predictive models that can accelerate target selection and the design and development of effective therapeutics.

Buoyant

Venture Round in 2019
Buoyant, Inc. builds an open source application programming interface (API) for mission-critical applications. The company develops Linkerd, an open source network proxy designed to be deployed as a service mesh. A service mesh is a dedicated layer for managing, controlling, and monitoring service-to-service communication within an application. The company was founded in 2015 and is headquartered in San Francisco, California.

Determined AI

Series A in 2019
Determined AI, founded in 2017 and based in San Francisco, California, specializes in developing a deep learning management platform that streamlines the process of building and deploying machine learning models. The company's platform enhances developer productivity by facilitating distributed training and hyperparameter searches, while also automating the tracking, sharing, and reproduction of experiments and metrics. This approach allows clients to significantly reduce their time-to-market, improve resource utilization, and mitigate risks associated with model development. Through its innovative software, Determined AI aims to transform the efficiency and effectiveness of deep learning workflows.

Owkin

Series A in 2019
Owkin is an artificial intelligence company founded in 2016, with headquarters in New York and an additional office in Paris. The company focuses on developing machine learning software for medical research, enabling researchers to test AI models on distributed data. Owkin's offerings include Owkin Lab, which facilitates data connectivity by therapeutic area; Owkin Loop, which provides validated and packaged models; and a comprehensive software stack for full-stack services. The company currently has 30 live models and an additional 40 in development. Owkin aims to empower medical researchers in hospitals, universities, and pharmaceutical companies to better understand variations in drug efficacy among patients, enhance the drug development process, and identify optimal treatments for individual patients, ultimately improving treatment outcomes. The company is supported by various investors and has a scientific board to guide its research initiatives.

Maze Therapeutics

Series A in 2019
Maze Therapeutics is a operator of a biotechnology firm intended to focused on translating genetic insights into new medicines. The company's translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, functional genomics and an array of drug discovery approaches.and its also reveals modifier genes that confer protection and provides deeper understanding of the target biology and how these targets can be targeted with drug therapies, enabling patients with protection against diseases.

Lightmatter

Series A in 2019
Lightmatter, Inc. is an artificial intelligence (AI) hardware company based in Boston, Massachusetts, that specializes in integrated optical technology to develop advanced computing processors. Founded in 2017, the company has created a silicon chip that utilizes light signals for processing, offering a new approach to AI computation. This technology accelerates critical operations in deep neural networks by employing programmable photonic elements alongside traditional transistors, enhancing the speed and efficiency of data processing while minimizing power consumption. Lightmatter's innovations aim to improve various AI applications, including image recognition and natural language processing, contributing to the advancement of next-generation AI-powered computing solutions.

Dandelion Energy

Series A in 2019
Dandelion Energy offers affordable geothermal heating and cooling installations. Dandelion Energy's home geothermal system replaces your home’s existing air conditioning and heating equipment with a powerful heat pump and safe, underground pipes that move heat between the earth and home. Kathleen Hannun and Rajeez Quazi founded it in 2017, with its headquarters in Palo Alto in California.

Dandelion

Series A in 2019
Dandelion's vision is to enable frictionless discovery of content and commerce. In a world where its easy for anyone to be a seller, it should be easy for anyone to be a marketer too. Dandelion provides the platform to storefronts, marketplaces, and their participants to make that happen.

Homebound

Series A in 2018
Homebound Inc. is a technology-driven custom home builder based in Santa Rosa, California, founded in 2017. The company specializes in constructing residential homes and offers a comprehensive range of support services, including architecture, design, financing, and insurance consultancy. Originating in response to the 2017 Northern California wildfires, Homebound aims to simplify the homebuilding process by providing a transparent and streamlined experience for homeowners. It manages the entire building journey, assisting clients from insurance negotiation and architectural design to permitting and construction. By leveraging user-friendly technology and a network of qualified building professionals, Homebound addresses the complexities and uncertainties homeowners face, particularly in the aftermath of natural disasters, enabling them to rebuild their homes more efficiently.

Machinify

Series A in 2018
Machinify, Inc. operates as a data-to-cash platform which enables enterprises to optimize core operations using artificial intelligence technology. It provides AI Cloud, which accepts and stores semi-structured and unstructured real-time data; AI Studio, which allows models to be built, tested, and iterated automatically by creating formulas in intuitive user interface; AI Runtime, which generates database infrastructure, feature computation jobs, and production APIs to make real-time or batch predictions. It offers software, data Science, and data engineering services. The company was founded in 2016 and is based in Palo Alto, California.

Kitchen United

Series A in 2018
Kitchen United, Inc. is a company that provides food production facilities specifically designed for restaurants and food service providers. Founded in 2017 and headquartered in Pasadena, California, it offers shared commercial kitchen spaces along with business intelligence solutions to support entrepreneurial caterers, pop-ups, mobile food vendors, and start-ups. By providing a turnkey solution, Kitchen United helps restaurant brands expand their operations with minimal risk and investment. Its facilities enable these businesses to efficiently produce food for pick-up and delivery, facilitating their entry into the food delivery market. The company operates locations in major cities across the United States, including Austin, Chicago, Los Angeles, San Francisco, New York City, and Scottsdale.

Lambda Inc.

Series A in 2018
Lambda Inc., doing business as Lambda School, provides online coding and computer science education training services in the United States. It provides training in computer science, software engineering, neural networks, artificial intelligence, and machine learning. The company also offers courses in JavaScript and website development. It provides online and live training sessions with instruction, hands-on projects, pair programming, and code reviews from instructors. The company was founded in 2016 and is based in San Francisco, California.

Yellowbrick Data

Series A in 2018
Yellowbrick Data was founded in 2014 by experts in database and flash memory technologies to simplify data warehousing. They wanted to solve the challenges of high availability, running complex mixed workloads, support for ad-hoc SQL, computing correct answers on any schema, massive scalability and supporting large numbers of concurrent users. Yellowbrick Data empowers companies to make faster decisions with all of their data. Built for enterprises and the hybrid cloud, the Yellowbrick Data Warehouse deploys powerful analytics anywhere, with best-in-class economics.

Blavity

Series A in 2018
Blavity, Inc. is a media tech company founded in 2014 and based in San Francisco, California. It operates an online community that caters to multicultural creators and influencers, primarily focusing on the lives of Black millennials and Gen Z. Blavity partners with content creators to expand their reach, amplify their messages, and support their entrepreneurial endeavors. The company is known for its diverse network of platforms and brands, delivering original content, videos, and unique experiences tailored to its audience.

Viz

Series A in 2018
Viz helps physicians to identify anomalies in brain scans through machine learning. The company leverages advanced deep learning to communicate time-sensitive information about stroke patients straight to a specialist who can intervene and treat. It uses deep learning algorithms to identify a suspected large vessel occlusion, a particularly disabling type of stroke, in a CT scan and alerts the stroke team specialist within minutes. Viz has developed deep learning algorithms to analyze brain scans for large vessel occlusions (LVOs), a disabling type of stroke. The company also allows the stroke center’s clinicians to rapidly share images back and forth. Viz's mission is to fundamentally improve how healthcare is delivered in the world, through intelligent software that promises to reduce time to treatment and improve access to care. Viz was founded in 2016 and is based in San Francisco, California, USA.

Openbay

Series A in 2018
Openbay, Inc. designs and develops SaaS based software for the automotive care industry. The company provides vehicle owners an online source for vehicle repair and maintenance needs. It connects customers with auto repair professionals that provide services, such as air conditioning services, battery replacements, belt replacements, brake pad and rotor replacements, exhaust system replacements, oil changes, radiator hose replacements, shock and strut replacements, spark plug replacements, steering component replacements, suspension component replacements, and tire replacements. The company was founded in 2011 and is based in Cambridge. Massachusetts.

Owkin

Series A in 2018
Owkin is an artificial intelligence company founded in 2016, with headquarters in New York and an additional office in Paris. The company focuses on developing machine learning software for medical research, enabling researchers to test AI models on distributed data. Owkin's offerings include Owkin Lab, which facilitates data connectivity by therapeutic area; Owkin Loop, which provides validated and packaged models; and a comprehensive software stack for full-stack services. The company currently has 30 live models and an additional 40 in development. Owkin aims to empower medical researchers in hospitals, universities, and pharmaceutical companies to better understand variations in drug efficacy among patients, enhance the drug development process, and identify optimal treatments for individual patients, ultimately improving treatment outcomes. The company is supported by various investors and has a scientific board to guide its research initiatives.

Celsius Therapeutics

Series A in 2018
Celsius Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that focuses on the development and research of innovative drugs. Established in 2017, the company utilizes single-cell genomic analysis and machine learning to gain insights into the cellular ecosystems of diseases. This approach allows Celsius Therapeutics to identify critical biomarkers that can enhance patient care and contribute to the creation of transformative medicines. The company's commitment to advancing the understanding of complex diseases positions it as a key player in the biotechnology sector.

Upbound

Series A in 2018
Upbound, Inc. develops and offers a multi-cloud platform that enables organizations to treat multiple disparate cloud environments as one. The company's platform allows organizations to build scalable multi-cloud services. Its platform allows for automation, cost optimization, capacity overflow, failover, policy enforcement, and portability across cloud environments. The company was founded in 2017 and is based in Seattle, Washington.

Insitro

Series A in 2018
Insitro is a operator of a data-driven drug discovery and development company that uses machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients. The company uses state-of-the-art technologies from Bioengineering enabling it to generate high-throughput, functional genomic data sets and aligning them with patient data via a novel machine learning methods, thereby building predictive models that can accelerate target selection and the design and development of effective therapeutics.

SambaNova Systems

Series A in 2018
SambaNova Systems is a computing startup focused on building machine learning and big data analytics platforms. The company's software defined analytics platform enables optimum performance for any ML training, inference or analytics models.

Blue Vision Labs

Series A in 2018
Blue Vision Labs Inc. is a technology company based in Los Angeles, California, specializing in augmented reality and machine perception for self-driving vehicles. Founded in 2016, the company aims to transform interaction between technology, users, and the environment through its innovative augmented reality cloud platform. This platform creates a three-dimensional map of urban spaces, allowing mobile devices to ascertain their location using visual data from cameras. This capability facilitates the development of collaborative augmented reality applications, enabling multiple users to interact with shared content in a precise spatial context. The team comprises engineers and researchers with backgrounds from prestigious organizations, focusing on advancements in robotics, computer vision, and related fields. As of 2018, Blue Vision Labs operates as a subsidiary of Lyft, Inc.

Voicea

Series A in 2018
Voicea is a technology company that specializes in artificial intelligence-based enterprise voice assistant software designed to enhance meeting productivity. Its flagship product, the Enterprise Voice Assistant (EVA), functions as an intelligent meeting facilitator by listening, taking notes, and identifying key decisions and action items during meetings. This capability allows users to make meetings searchable and ensures that discussions translate into actionable initiatives. Founded in 2016 and headquartered in Menlo Park, California, Voicea was formerly known as Voicera until its rebranding in December 2018. The company operates as a subsidiary of Cisco Systems, Inc., and is led by professionals with experience from major technology firms.

Vaccitech

Series A in 2018
Vaccitech Limited researches and develops T cell immunotherapeutic products and vaccines. The company offers hepatitis B virus (HBV) and human papillomavirus (HPV) therapeutic products and therapeutic vaccines for prostate cancer. The company was incorporated in 2016 and is based in Oxford, United Kingdom.